tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Dec 18;24(1):1428.
doi: 10.1186/s12879-024-10324-0. Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B
Tong Sun[SUP] #[/SUP][SUP] 1 [/SUP], Hongbo Chi[SUP] #[/SUP][SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Yufen Zheng[SUP] 1 [/SUP], Hongguo Zhu[SUP] 1 [/SUP], Jingxian Zhao[SUP] 1 [/SUP], Kai Zhou[SUP] 1 [/SUP], Mengyuan Chen[SUP] 1 2 [/SUP], Donglian Wang[SUP] 1 [/SUP], Tao-Hsin Tung[SUP] 3 [/SUP], Jiaqin Xu[SUP] 1 [/SUP], Bo Shen[SUP] 4 5 [/SUP]
Affiliations
Objective: To investigate the impact of SARS-CoV-2 infection on liver function and prognosis in patients with HBV infection.
Methods: A total of 154 HBV-positive patients (HBV ( +) group) and 154 HBV-negative patients (HBV (-) group) diagnosed with COVID-19 at Taizhou Hospital between December 10, 2022, and January 31, 2023, were included in this study. Clinical characteristics, treatment, and laboratory findings were collected from patients at three time points: before (T1), during (T2), and at the time of discharge (T3) from SARS-CoV-2 infection.
Results: Compared to the HBV (-) group, the HBV ( +) group had a longer hospital stay (15 (9-22) days vs. 9 (5-16) days). Longitudinal comparisons of laboratory indicators from T1 to T3 showed a continuous decline in TP and ALB levels and a continuous increase in PT and TT levels in the HBV ( +) group. BUN levels increased during T2 and decreased thereafter. These differences were considered statistically significant (P < 0.05). Notably, the HBV ( +) group had a higher proportion of indicators elevated > 3 ULN from T1 to T2, including ALT (1.95%/5.19%), AST (3.25%/12.99%), ALP (1.95%/3.25%), GGT (4.55%/9.09%), TBIL (6.49%/9.09%), and DBIL (18.18%/22.73%). In the HBV (-) group, the elevations were mainly concentrated within 1-2 ULN, including AST (12.99%/22.08%), DBIL (10.39%/21.43%), BUN (12.99%/22.08%), CREA (20.13%/29.22%), and PLT (7.79%/14.94%). Furthermore, the incidence of liver injury from T1 to T3 was higher in the HBV ( +) group compared to the HBV (-) group (15.7% (20/127) vs. 7.2% (11/152), P < 0.05). Multivariate analysis showed that liver cirrhosis (HR = 4.847, 95% CI: 1.224-19.20, P = 0.025) and liver cancer (HR = 8.333, 95% CI: 2.156-32.209, P = 0.002) were independent risk factors for liver injury in the presence of SARS-CoV-2 infection.
Conclusion: SARS-CoV-2 infection has a higher proportion of liver injury in HBV-infected patients, affecting hepatic protein synthesis function. Those with cirrhosis and hepatocellular carcinoma are at higher risk of severe liver injury.
Keywords: HBV; Liver function; Liver injury; SARS-CoV-2.
. 2024 Dec 18;24(1):1428.
doi: 10.1186/s12879-024-10324-0. Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B
Tong Sun[SUP] #[/SUP][SUP] 1 [/SUP], Hongbo Chi[SUP] #[/SUP][SUP] 1 [/SUP], Jing Wang[SUP] 1 [/SUP], Yufen Zheng[SUP] 1 [/SUP], Hongguo Zhu[SUP] 1 [/SUP], Jingxian Zhao[SUP] 1 [/SUP], Kai Zhou[SUP] 1 [/SUP], Mengyuan Chen[SUP] 1 2 [/SUP], Donglian Wang[SUP] 1 [/SUP], Tao-Hsin Tung[SUP] 3 [/SUP], Jiaqin Xu[SUP] 1 [/SUP], Bo Shen[SUP] 4 5 [/SUP]
Affiliations
- PMID: 39695950
- DOI: 10.1186/s12879-024-10324-0
Objective: To investigate the impact of SARS-CoV-2 infection on liver function and prognosis in patients with HBV infection.
Methods: A total of 154 HBV-positive patients (HBV ( +) group) and 154 HBV-negative patients (HBV (-) group) diagnosed with COVID-19 at Taizhou Hospital between December 10, 2022, and January 31, 2023, were included in this study. Clinical characteristics, treatment, and laboratory findings were collected from patients at three time points: before (T1), during (T2), and at the time of discharge (T3) from SARS-CoV-2 infection.
Results: Compared to the HBV (-) group, the HBV ( +) group had a longer hospital stay (15 (9-22) days vs. 9 (5-16) days). Longitudinal comparisons of laboratory indicators from T1 to T3 showed a continuous decline in TP and ALB levels and a continuous increase in PT and TT levels in the HBV ( +) group. BUN levels increased during T2 and decreased thereafter. These differences were considered statistically significant (P < 0.05). Notably, the HBV ( +) group had a higher proportion of indicators elevated > 3 ULN from T1 to T2, including ALT (1.95%/5.19%), AST (3.25%/12.99%), ALP (1.95%/3.25%), GGT (4.55%/9.09%), TBIL (6.49%/9.09%), and DBIL (18.18%/22.73%). In the HBV (-) group, the elevations were mainly concentrated within 1-2 ULN, including AST (12.99%/22.08%), DBIL (10.39%/21.43%), BUN (12.99%/22.08%), CREA (20.13%/29.22%), and PLT (7.79%/14.94%). Furthermore, the incidence of liver injury from T1 to T3 was higher in the HBV ( +) group compared to the HBV (-) group (15.7% (20/127) vs. 7.2% (11/152), P < 0.05). Multivariate analysis showed that liver cirrhosis (HR = 4.847, 95% CI: 1.224-19.20, P = 0.025) and liver cancer (HR = 8.333, 95% CI: 2.156-32.209, P = 0.002) were independent risk factors for liver injury in the presence of SARS-CoV-2 infection.
Conclusion: SARS-CoV-2 infection has a higher proportion of liver injury in HBV-infected patients, affecting hepatic protein synthesis function. Those with cirrhosis and hepatocellular carcinoma are at higher risk of severe liver injury.
Keywords: HBV; Liver function; Liver injury; SARS-CoV-2.